India’s alarming ‘fixed dose combination’ problem

Subject: Science and Tech

Section: Health

Concept:

Antimicrobial resistance is at risk due to the study’s shocking findings on the frequency of antibiotics’ unapproved and illegal Fixed Dose Combinations (FDCs) in India.
Public health requires immediate action in response to the pharmaceutical industry’s use of FDCs as a means of circumventing legislation and regulatory inefficiencies.

Historical Aspect:

Tracing the issue back to 1978 and subsequent regulatory amendments provides context to the ongoing challenges.

Key Highlights:

Alarming Prevalence: In 2020, 60.5% of antibiotics in India were unapproved FDCs, with an additional 9.9% banned, raising concerns about antimicrobial resistance.
Patient Compliance vs. Risks: FDCs, aimed at improving patient adherence, pose risks due to potential interactions between combined drugs, necessitating a stringent approval process.
Pharmaceutical Industry’s Strategy: Exploitation of FDCs allows the industry to evade drug price regulations, contributing to the proliferation of irrational combinations.

Key Terms:

Fixed Dose Combination (FDC): Combinations of multiple drugs in a single dosage form, potentially affecting drug interactions and therapeutic efficacy.
Antimicrobial Resistance (AMR): The ability of microorganisms to resist the effects of medications, posing a global health threat.

Key Challenges:

Continued sale of unapproved FDCs highlights regulatory inefficiency, allowing non-compliance despite existing legal provisions.

Reliance on Section 26A orders reveals a reactive rather than proactive regulatory approach, indicating systemic challenges.

Key Issues:

Pharmaceutical Industry’s Exploitation: The strategic use of FDCs to avoid regulatory scrutiny undermines the integrity of drug pricing and quality.
Ineffectiveness of Regulatory Measures: Despite legal provisions, the regulatory system relies on reactive prohibitions rather than proactive prevention.